VERTEX PHARMACEUTICALS INC / MA Other Comprehensive Income (Loss), before Reclassifications, Net of Tax
VERTEX PHARMACEUTICALS INC / MA (VRTX) reported Other Comprehensive Income (Loss), before Reclassifications, Net of Tax of -$69.42 million for the 12-month period ending 2020-12-31, per its 10-K filed 2021-02-11.
Discontinued › Income Statement › Unrealized Gains
us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax · last filed 2021-02-11
- VERTEX PHARMACEUTICALS INC / MA other comprehensive income (loss), before reclassifications, net of tax for the quarter ending 2018-12-31 was $6.54M, a 31.28% decline year-over-year.
- VERTEX PHARMACEUTICALS INC / MA other comprehensive income (loss), before reclassifications, net of tax for the quarter ending 2018-09-30 was $6.63M.
- VERTEX PHARMACEUTICALS INC / MA other comprehensive income (loss), before reclassifications, net of tax for the quarter ending 2018-06-30 was $32.23M.
- VERTEX PHARMACEUTICALS INC / MA other comprehensive income (loss), before reclassifications, net of tax for the quarter ending 2018-03-31 was -$10.83M.
- VERTEX PHARMACEUTICALS INC / MA other comprehensive income (loss), before reclassifications, net of tax for fiscal 2020 was -$69.42M, a 403.35% decline from fiscal 2019.
- VERTEX PHARMACEUTICALS INC / MA other comprehensive income (loss), before reclassifications, net of tax for fiscal 2019 was $22.88M, a 33.82% decline from fiscal 2018.
- VERTEX PHARMACEUTICALS INC / MA other comprehensive income (loss), before reclassifications, net of tax for fiscal 2018 was $34.58M.
- VERTEX PHARMACEUTICALS INC / MA other comprehensive income (loss), before reclassifications, net of tax for fiscal 2017 was -$35.39M, a 222.05% decline from fiscal 2016.
| Period end | Other Comprehensive Income (Loss), before Reclassifications, Net of Tax 3 month | Other Comprehensive Income (Loss), before Reclassifications, Net of Tax 6 month | Other Comprehensive Income (Loss), before Reclassifications, Net of Tax 9 month | Other Comprehensive Income (Loss), before Reclassifications, Net of Tax 12 month |
|---|---|---|---|---|
| 2020-12-31 | -$69.42M 10-K · filed 2021-02-11 | |||
| 2019-12-31 | $22.88M 10-K · filed 2021-02-11 | |||
| 2018-12-31 | $6.54M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-11 | $13.17M derived: sum of 2 quarters · filed 2021-02-11 | $45.41M derived: sum of 3 quarters · filed 2021-02-11 | $34.58M 10-K · filed 2021-02-11 |
| 2018-09-30 | $6.63M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-10-25 | $38.87M derived: sum of 2 quarters · filed 2018-10-25 | $28.04M 10-Q · filed 2018-10-25 | $37.55M derived: sum of 4 quarters · filed 2020-02-13 |
| 2018-06-30 | $32.23M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-07-26 | $21.41M 10-Q · filed 2018-07-26 | $30.92M derived: sum of 3 quarters · filed 2020-02-13 | $24.23M derived: sum of 4 quarters · filed 2020-02-13 |
| 2018-03-31 | -$10.83M 10-Q · filed 2018-04-27 | -$1.31M derived: sum of 2 quarters · filed 2020-02-13 | -$8.00M derived: sum of 3 quarters · filed 2020-02-13 | -$44.95M derived: sum of 4 quarters · filed 2020-02-13 |
| 2017-12-31 | $9.51M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-13 | $2.83M derived: sum of 2 quarters · filed 2020-02-13 | -$34.12M derived: sum of 3 quarters · filed 2020-02-13 | -$35.39M 10-K · filed 2020-02-13 |
| 2017-09-30 | -$6.69M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-10-25 | -$43.63M derived: sum of 2 quarters · filed 2018-10-25 | -$44.90M 10-Q · filed 2018-10-25 | -$15.02M derived: sum of 4 quarters · filed 2019-02-13 |
| 2017-06-30 | -$36.95M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-07-26 | -$38.22M 10-Q · filed 2018-07-26 | -$8.33M derived: sum of 3 quarters · filed 2019-02-13 | -$6.07M derived: sum of 4 quarters · filed 2019-02-13 |
| 2017-03-31 | -$1.27M 10-Q · filed 2018-04-27 | $28.62M derived: sum of 2 quarters · filed 2019-02-13 | $30.88M derived: sum of 3 quarters · filed 2019-02-13 | $33.06M derived: sum of 4 quarters · filed 2019-02-13 |
| 2016-12-31 | $29.89M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-13 | $32.15M derived: sum of 2 quarters · filed 2019-02-13 | $34.33M derived: sum of 3 quarters · filed 2019-02-13 | $29.00M 10-K · filed 2019-02-13 |
| 2016-09-30 | $2.26M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-10-31 | $4.45M derived: sum of 2 quarters · filed 2016-10-31 | -$890.00K 10-Q · filed 2016-10-31 | $649.00K derived: sum of 4 quarters · filed 2018-02-15 |
| 2016-06-30 | $2.18M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-01 | -$3.15M 10-Q · filed 2016-08-01 | -$1.61M derived: sum of 3 quarters · filed 2018-02-15 | $2.50M derived: sum of 4 quarters · filed 2018-02-15 |
| 2016-03-31 | -$5.34M 10-Q · filed 2016-05-03 | -$3.80M derived: sum of 2 quarters · filed 2018-02-15 | $315.00K derived: sum of 3 quarters · filed 2018-02-15 | -$1.28M derived: sum of 4 quarters · filed 2018-02-15 |
| 2015-12-31 | $1.54M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-15 | $5.65M derived: sum of 2 quarters · filed 2018-02-15 | $4.06M derived: sum of 3 quarters · filed 2018-02-15 | $5.63M 10-K · filed 2018-02-15 |
| 2015-09-30 | $4.11M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-10-31 | $2.52M derived: sum of 2 quarters · filed 2016-10-31 | $4.09M 10-Q · filed 2016-10-31 | $4.98M derived: sum of 4 quarters · filed 2016-10-31 |
| 2015-06-30 | -$1.59M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-01 | -$20.00K 10-Q · filed 2016-08-01 | $866.00K derived: sum of 3 quarters · filed 2016-08-01 | $2.46M derived: sum of 4 quarters · filed 2016-08-01 |
| 2015-03-31 | $1.57M 10-Q · filed 2016-05-03 | $2.46M derived: sum of 2 quarters · filed 2016-05-03 | $4.05M derived: sum of 3 quarters · filed 2016-05-03 | $4.35M derived: sum of 4 quarters · filed 2016-05-03 |
| 2014-12-31 | $886.00K derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-16 | $2.48M derived: sum of 2 quarters · filed 2016-02-16 | $2.77M derived: sum of 3 quarters · filed 2016-02-16 | $2.78M 10-K · filed 2016-02-16 |
| 2014-09-30 | $1.59M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-10-30 | $1.89M derived: sum of 2 quarters · filed 2015-10-30 | $1.89M 10-Q · filed 2015-10-30 | $2.14M derived: sum of 4 quarters · filed 2016-02-16 |
| 2014-06-30 | $294.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-04 | $300.00K 10-Q · filed 2015-08-04 | $544.00K derived: sum of 3 quarters · filed 2016-02-16 | |
| 2014-03-31 | $6.00K 10-Q · filed 2015-05-04 | $250.00K derived: sum of 2 quarters · filed 2016-02-16 | ||
| 2013-12-31 | $244.00K derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-16 | $244.00K 10-K · filed 2016-02-16 | ||
| 2013-09-30 | $0.00 10-Q · filed 2014-11-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |